Contraception (Birth Control) and Family Planning PubHealthInfo

[PubHealth.info Homepage] [Category Homepage] [Disclaimer/Copyrights] [Feedback]

Thank you for your kind visit to PubHealth.info®, an information portal created in technical collaboration with PakMed Biomedical Solutions * * * PubHealth.info® presents hundreds of thousands of informative Web pages on a variety of public health issues / issues * * * An ultimate source of information for teachers, students and research workers who need to find information on various public health issues, like population planning, contraception, HIV AIDS, STDs, maternal and child health, communicable and non-communicable disease, etc. * * * PubHealth.info® regularly updates the repository of these hundreds of thousands of informative Web pages * * * PubHealth.info® is one of the world's largest repositories and information portals with online Web pages on public health issues particularly those pertaining to developing countries!

PubHealth.info® (a subsidiary of PakMed) presents scientific information mainly based on abstracts of articles published on a variety of public health issues/topics, particularly encompassing population planning, disease prevention, maternal and child health, and communicable and non-communicable diseases (like HIV AIDS, malaria, etc) that are affecting a significant portion of population in developing and developed countries. Here you can find abstracts of articles published on a variety of public health topics under category "Contraception (Birth Control) and Family Planning". Contraception (birth control) is a regimen of one or more actions, devices, or medications followed in order to deliberately prevent or reduce the likelihood of a woman becoming pregnant or giving birth. Therefore contraception is the utilization of various and sundry surgical procedures, devices, practices, agents, or drugs with the intention of preventing conception or impregnation (pregnancy). Methods and intentions typically termed birth control may be considered a pivotal ingredient to family planning. Birth control is a controversial political and ethical issue in many cultures and religions, and although it is generally less controversial than abortion specifically.

YEAR: 1993

CATEGORY: Contraception (Birth Control) and Family Planning

TITLE

A prospective randomized comparison of levonorgestrel with the Yuzpe regimen

in post-coital contraception.

AUTHORS

Ho PC; Kwan MS

SOURCE

HUMAN REPRODUCTION. 1993 Mar;8(3):389-92.

ABSTRACT

A prospective, randomized study was conducted at the Family Planning Association of Hong Kong to compare the

efficacy of the Yuzpe regimen and levonorgestrel (0.75 mg for 2 doses 12 hours apart) in post-coital contraception. A

total of 424 subjects were recruited into the Yuzpe group and 410 subjects into the levonorgestrel group; 77 subjects

in the Yuzpe group and 79 subjects in the levonorgestrel group had further acts of intercourse during the treatment

cycle. 15 pregnancies (3.5%)occurred in the Yuzpe group and 12 pregnancies (2.9%) in the levonorgestrel group.

After excluding the patients who had further acts of intercourse, the failure rates in the Yuzpe group and the

levonorgestrel group were 2.6 and 2.4, respectively. The incidence of nausea, vomiting, and fatigue in the Yuzpe

group was significantly higher than in the levonorgestrel group. The authors conclude that levonorgestrel is an

effective drug for post-coital contraception with a lower incidence of side effects than the Yuzpe regimen.

(PubHealth.info Document ID: CONT2T 4567-06)

PubHealth.info NOTE: The author(s) of this article titled, "A prospective randomized comparison of levonorgestrel

with the Yuzpe regimen in post-coital contraception.", is(are) Ho PC; Kwan MS. The source of this article is

"HUMAN REPRODUCTION. 1993 Mar;8(3):389-92.". This article was published in 1993 in English language(s).

(PubHealth.info® Document ID: CONT2T 4567-06. All rights reserved with PubHealth.info) PIN: 9567

This article is peer-reviewed.

This page is optimized to be viewed by Java script enabled Microsoft® Internet Explorer 6 or later version, at screen resolution of 800 by 600 pixels.